Contineum Therapeutics (CTNM) Operating Income (2023 - 2024)
Historic Operating Income for Contineum Therapeutics (CTNM) over the last 2 years, with Q4 2024 value amounting to -$17.0 million.
- Contineum Therapeutics' Operating Income fell 7617.82% to -$17.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$50.9 million, marking a year-over-year decrease of 41657.03%. This contributed to the annual value of -$50.9 million for FY2024, which is 41656.4% down from last year.
- As of Q4 2024, Contineum Therapeutics' Operating Income stood at -$17.0 million, which was down 7617.82% from -$13.0 million recorded in Q3 2024.
- Contineum Therapeutics' Operating Income's 5-year high stood at $38.9 million during Q2 2023, with a 5-year trough of -$17.0 million in Q4 2024.